Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Interest ReceivablesChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Depreciation & Amortization (CF): 2024-2025

  • Abivax's Depreciation & Amortization (CF) fell 27.72% to $284,122 in Q2 2025 from the same period last year, while for Jun 2025 it was $1.2 million, marking a year-over-year change of. This contributed to the annual value of $1.2 million for FY2024, which is 54.52% up from last year.
  • As of Q2 2025, Abivax's Depreciation & Amortization (CF) stood at $284,122, which was down 1.06% from $287,164 recorded in Q1 2025.
  • Over the past 5 years, Abivax's Depreciation & Amortization (CF) peaked at $393,064 during Q2 2024, and registered a low of $229,222 during Q1 2024.
  • In the last 2 years, Abivax's Depreciation & Amortization (CF) had a median value of $285,643 in 2025 and averaged $298,393.
  • Data for Abivax's Depreciation & Amortization (CF) shows a peak YoY increase of 25.28% (in 2025) and a maximum YoY decrease of 27.72% (in 2025) over the last 5 years.
  • Abivax's Depreciation & Amortization (CF) (Quarterly) stood at $393,064 in 2024, then fell by 27.72% to $284,122 in 2025.
  • Its last three reported values are $284,122 in Q2 2025, $287,164 for Q1 2025, and $393,064 during Q2 2024.